Geneva, May 18 -- International Clinical Trials Registry received information related to the study (ChiCTR2600124193) titled 'A single-arm, prospective, open-label clinical study of adebrelimab combined with anti-angiogenic drugs and gemcitabine/cisplatin as first-line treatment for advanced biliary tract tumors' on May 8.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Henan Cancer Hospital

Condition: Biliary tract tumor

Recruitment Status: Recruiting

Phase: 4

Date of First Enrollment: 2025-02-04

Target Sample Size: treatment group:58;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=305850

Published by HT Digital Content Services with permission ...